Erkki Soini

Verified

Erkki verified their affiliation via an institutional email.

Learn more

Verified

Erkki verified their affiliation via an institutional email.

Learn more

• MSc, RNS
• CEO at ESiOR Oy

Objective This nationwide retrospective chart review study assessed ustekinumab treatment persistence and clinical outcomes of ustekinumab treatment in Finnish patients with ulcerative colitis in a real-world setting. Methods Data was collected retrospectively until April 2022 from patient charts for all patients with ulcerative colitis who starte...

Treatment patterns of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland are unknown. Guidelines now recommend early escalation of treatment for PAH. We evaluated how well Finnish practice follows guidelines, and how treatment initiations and outcomes are related. The pulmonary arterial hypert...

Diffractive trifocal intraocular lenses (IOLs) provide good vision at distance, intermediate, and near, but can also cause positive dysphotopsias. This meta-analysis pooled published evidence on visual disturbances after bilateral implantation of the PanOptix (TFNTXX) IOL for patients undergoing cataract surgery. A systematic literature search was...

Background To assess characteristics, risk group distribution, and prognosis of patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) in Finland. Methods Clinical chart review of patients with PAH or CTEPH recorded between 2008 and 2019 and linkage to official mortality data. Results We ident...

Saatavilla: https://www.laaketeollisuus.fi/media/julkaisut/esitteita-ja-raportteja/240611-ltlt1-esior-laaketutkimuksen-yhteiskunnallinen-arvo-loppuraportti-11.6.2024.pdf

Webinaari 15.2.2024: Rekisteritutkimukset: Terveydenhuollon virstanpylväitä. Pharmaca Health Intelligence

Background Treatment of pulmonary arterial hypertension (PAH) with triple therapy (TriT) including phosphodiesterase type-5 inhibitors (PDE5), endothelin receptor antagonists (ERA), and prostacyclin receptor agonists (PRA) or analogues (PCA) is indicated in severe PAH. There is evidence of benefit also in intermediate-risk patients. Purpose To des...

Purpose Sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin has recently been shown to improve the outcomes of heart failure (HF) patients regardless of patient’s left ventricular ejection fraction by reducing the combined risk of cardiovascular death or hospitalization for worsening HF. The aim of this study was to assess the cost-effec...

Introduction: Intravenous infusion therapy is a common and challenging invasive treatment procedure in hospital wards. Administration mistakes can have serious, even life-threatening, consequences. The Monidor solution was developed to help nurses administer gravity-based infusions and monitor them remotely, to avoid complications and reduce workl...

Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was comm...

Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in Finland. DOACs have been shown to be cost-effective in comparison to warfarin, but published evidence of relative cost-effectiveness between DOACs is still scarce and mostly...

Objectives Chronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators ti...

Background Real-world evidence to support optimal ustekinumab dosing for refractory Crohn’s disease (CD) patients remains limited. Data from a retrospective nationwide chart review study was utilized to explore ustekinumab dosing dynamics and optimization, identify possible clinical predictors of dose intensification, and to evaluate ustekinumab tr...

Objective: Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn's disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn's disease patients treated with ustekinumab. Methods: The study was conducted in 17 Finnish hospital...

Introduction: Currently, 15-20% of individuals with coronary artery disease (chronic coronary syndrome [CCS]) or peripheral artery disease (PAD) receiving routine treatment experience cardiovascular events (CVEs) within 3-4 years. Using PICOSTEPS (Patients-Intervention-Comparators-Outcomes-Setting-Time-Effects-Perspective-Sensitivity analysis) rep...

Background Real-life long-term evidence on ustekinumab treatment in patients with Crohn’s disease (CD) is limited. We performed a retrospective non-interventional nation-wide chart review study of dosing and long-term clinical outcomes in Finnish CD patients treated with ustekinumab (FINUSTE2, EUPAS30920). Methods FINUSTE2 was carried out in 17 Fi...

Background Real-life long-term evidence on ustekinumab treatment response in patients with Crohn’s disease (CD) is scarce. We performed a retrospective non-interventional nationwide chart review study of dosing and long-term clinical outcomes in Finnish CD patients treated with ustekinumab (FINUSTE2, EUPAS30920). Methods FINUSTE2 involved 17 Finni...

Introduction: Cost assessment modelling (CAM) of treatments in highly active relapsing multiple sclerosis was conducted. Methods: The CAM was developed using the R programming language. The PICOSTEPS health technology assessment framework was applied in the CAM. Modelled patients were 280 adults with highly active relapsing multiple sclerosis el...

Introduction There is an unmet need for well-tolerated antiepileptic drugs (AEDs) that effectively control focal onset seizures. This study aimed to evaluate the economic value of new AEDs in the treatment of focal onset seizure, with or without secondary generalization, in Finnish adults and adolescents with epilepsy, comparing brivaracetam with p...

HealthyWeighHub (HWH) is a 12-month coaching and education service designed to help patients with obesity make permanent life changes, launched and expanded gradually in Helsinki University Hospital (HUS) Healthvillage since 2016. We examined the direct secondary care cost benefits of HWH, measured with potential capacity freed (PCF) compared to c...

Background and Aims: A retrospective non-interventional, multi-centre patient chart review study was conducted to investigate the association of faecal calprotectin (FC) 1 year (±2 months) after biological therapy initiation with composite event-free survival (CEFS) consisting of surgical procedures, corticosteroid initiation, treatment failure or...

Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn’s Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patients receiving UST to provide guidance in UST treatment in the era of increasing prevalence of CD. Met...

Background: Generally, in a society working with efficiency and budget requirements (i.e., limited resources), the aim should be to provide maximal effectiveness efficiently with the given inputs (technical efficiency) based on optimal decision criteria (allocative efficiency). Health economics and outcomes research (HEOR) can also pursue effective...

Background: Finnish government has aimed at responsive and efficient use of healthcare data [1]. An essential part of efficient real-world data use is the process consisting of data – analysis – knowledge management – communication. For that purpose, the Finnish Innovation Fund Sitra funded Isaacus pre-production projects [2] that were aimed at pre...

Background: Virtual hospital 2.0 (VH2.0, Virtuaalisairaala 2.0) platform, a joint project between all Finnish university hospitals [1] is an essential part of the Finnish governmental wellbeing project of customer-responsive services [2–3]. Virtual village (Terveyskylä [4]) of VH2.0 produces and implements client-oriented digital special care servi...

Background: Virtual hospital 2.0 (VH2.0, Virtuaalisairaala 2.0) platform, a joint project between all Finnish university hospitals [1] is an essential part of a key governmental wellbeing project of customer-responsive services in Finland [2–3]. VH2.0 produces and implements client-oriented digital special care services to various stakeholders (e.g...

Background: Virtual Hospital 2.0 (VH2.0, Virtuaalisairaala 2.0) and its platform are essential parts of a key governmental wellbeing project of customer-responsive services in Finland and based on a joint project of all Finnish university hospitals [1–3]. VH2.0 produces and implements client-oriented digital special care services to patients, provi...

Background There is limited real-life data on ustekinumab (UST) treatment in patients diagnosed with Crohn’s disease (CD). The present study is a retrospective non-interventional chart review of dosing and short-term clinical outcomes in patients with CD who were treated with UST in Finland (FINUSTE, EUPAS 24728 registration). The aim of the study...

Aim: To estimate the drug administration, travelling, and productivity costs associated with infusion or subcutaneous proteasome inhibitor (PI) treatments (specifically carfilzomib and bortezomib) for multiple myeloma (MM) patients in Finland. Materials and methods: Price tariffs of Finnish hospital districts are used as the basis of invoicing sent...

Context: Virtual hospital 2.0 (VH2.0, www.virtuaalisairaala2.fi), a joint project between Finnish university hospitals, is novel, client-oriented digital specialised care service practice for citizens, patients and professionals. Currently 85 patient groups and some 80,000 visitors/month use existing 20 houses of VH2.0 Health Village (www.terveysky...

Terveys ja Talous 2018;(5):36-7

KVR SHEOG -tilaisuus, UEF

https://hoivajaterveys.fi/erkki-soini-sosiaali-ja-terveydenhuollon-kustannusvaikuttavuutta-on-tarkeinta-pohtia-asiakkaan-saaman-hyodyn-kannalta/

Purpose Osteoporosis is asymptomatic morbidity of the elderly which develops slowly over several years. Osteoporosis diagnosis has typically involved Fracture Risk Assessment (FRAX) followed by dual energy X-ray absorptiometry (DXA) in specialist care. Point-of-care pulse-echo ultrasound (PEUS) was developed to overcome DXA-related access issues an...

BestPractice Reumasairaudet 2018;6(17):16-18. Ehdollinen korvattavuus ja siihen liittyvä riskinjako ovat Suomessa korvattujen lääkevalmisteiden osalta tuore, mutta pitkään odotettu mahdollisuus. Kokemukset ensimmäisestä vuodesta ja taloussopimuksista ovat olleet positiiviset, mutta toistaiseksi käytössä ei ole vielä yhtään tulossopimusta. Tuore su...

Background Fecal calprotectin (fCal) has been shown to correlate well with endoscopic healing in Crohn’s disease (CD) patients, while less evidence is available on the association of fCal and long-term outcomes such as the need for surgeries. This study was established to analyse whether the surgery free survival (SFS) is associated with the attain...

Purpose: To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-naïve patients) versus the current mix of reimbursed biologics for treatment of moderate-to-severe rheumatoid arthritis (R...

The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a collaborative effort by ESiOR Oy, Abbvie Oy, The Crohn and Colitis association (Crohn ja Colitis ry), Confederation of Finnish Industries (EK), The Finnish Medical Association...

Full text available: http://onlinelibrary.wiley.com/doi/10.1002/ehf2.12179/full Aims Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality o...

What is primary care patient's quality of life?

Supplementary material for the Cost-effectiveness of biologics in psoriatic arthritis work for the Finnish Current Care Criteria of psoriasis. Available: http://www.terveysportti.fi/xmedia/nix/nix02465liitteet.pdf

Cost-effectiveness of apixaban. Shorter version of article published in the Springer+ Journal. https://bestprac.fi/2017/03/22/apiksabaanin-kustannusvaikuttavuus-eteisvarinapotilailla/

Cost-effectiveness of biologic disease-modifying treatments in psoriatic arthritis. Work for the Finnish Current Care Criteria: Psoriasis. Available: http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=nix02465&suositusid=hoi50062

Purpose: This study evaluated the cost-effectiveness of first-line treatments of relapsing-remitting multiple sclerosis (RRMS) (dimethyl fumarate [DMF] 240 mg PO BID, teriflunomide 14 mg once daily, glatiramer acetate 20 mg SC once daily, interferon [IFN]-β1a 44 µg TIW, IFN-β1b 250 µg EOD, and IFN-β1a 30 µg IM QW) and best supportive care (BSC) in...

Background To reduce the risk of thromboembolic complications, clinical guidelines recommend anticoagulation treatment for almost all atrial fibrillation (AF) patients. Although warfarin has long been the primary treatment alternative, now newer alternatives such as apixaban have proven effective in prevention of the thromboembolic complications of...

Objectives: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the Finnish setting in major depressive disorder (MDD) patients with inadequate response to selective serotonin- /serotonin–norepinephrine reuptake inhibitors. Methods: A one-year analysis was conducted u...

Cost-effectiveness of CLL in Finland and its new interpretations: Clinical cost-benefit analysis and impact investment

See: http://spo.escardio.org/SessionDetails.aspx?eevtid=1126&sessId=19212&subSessId=0#.V1WWk-SnZzJ

See: http://epublications.uef.fi/pub/urn_isbn_978-952-61-2130-7/urn_isbn_978-952-61-2130-7.pdf

See: http://epublications.uef.fi/pub/urn_isbn_978-952-61-2130-7/urn_isbn_978-952-61-2130-7.pdf

Purpose: The cost-effectiveness of first-line chronic lymphocytic leukemia treatments was assessed among patients unsuitable for full doses of fludarabine. Methods: The study's key outcome was the life-time incremental cost-effectiveness ratio (ICER) (euro/quality-adjusted life-year [QALY] gained) with an annual 3% discounting. A probabilistic M...

Objective To explore patient characteristics, resource use, and costs related to different episodes of care (EOC) in Finnish health care.Design Data were collected during a three-month prospective, non-randomized follow-up study (Effective Health Centre) using questionnaires and an electronic health record.Setting Three primary health care practice...